YouTube Facebook LinkedIn Google+ Twitter Xinginstagram rss  

Genedata Announces Software Suite for Biologics R&D

Genedata Biologics automatically identifies the most promising screening hits based on assay readouts and sequence characteristics.

By Allison Proffitt

March 29, 2011
| SAN FRANCISO—Genedata released Genedata Biologics, a first-in-class, off-the-shelf software solution for comprehensive data management and analysis of biologics R&D activities at CHI’s Molecular Medicine Tri-Conference 2011* in San Francisco in February.

“The biologics market is expected to reach $158 billion by 2015 and an increasing number of biologics drugs are being approved and marketed,” Othmar Pfannes, CEO of Genedata, told Bio•IT World. “We have made significant investments in R&D and product development to deliver a solution that customers need to effectively participate in the quickly evolving biologics market,”

Genedata Biologics enables pharmaceutical and biotechnology research organizations to efficiently discover and develop novel protein-based therapies while enabling registration of all relevant biomaterials to provide a historical record in support of downstream development and production of therapeutic proteins.

Genedata expects the product to appeal to big pharma in the process of building up internal biologics R&D operations parallel to existing small-molecule R&D processes; established biotechs with significant in-house legacy software requiring life cycle replacements to address new R&D requirements; small and medium biotechs and CROs with only sub-critical resources to develop or maintain software in-house; and companies in the quickly-growing biosimilars/generics market.

Genedata Biologics is the fruit of collaborations between Genedata and several pharmaceutical and biotech partners including Bayer HealthCare AG said Pfannes. “Based on more than four years of development in close collaboration with international pharma and biotech customers, Genedata Biologics is the first commercial, off-the-shelf software solution to provide an integrated platform for biologics-specific discovery and development processes, ranging from biologics screening to the production of protein therapeutics.”

“Our collaboration with Genedata to develop a biologics data platform has been very successful,” said Clive Wood, head of global biologics at Bayer HealthCare AG in a press release. “A commercial data management solution such as this has been sorely lacking in protein therapeutics.”

Genedata Biologics leverages IP in screening and sequence analysis, which is the result of Genedata’s Screener and Phylosopher businesses, while integrating complex and interconnected workflows from different research groups and supports work in division-of-labor environments. Standardized interfaces help document and manage a broad range of activities such as antibody screening (including phage display or hybridoma), cloning, molecular biology, protein expression and purification, analytics, and cell line development.

In addition, the system provides functionalities to facilitate data and material handovers among different departments and external service providers and provides built-in business- and lab-logic with integration capabilities to company-specific infrastructure and processes.

The Oracle-based database enables consistent storage and referencing of all relevant biomaterials such as antibody clones, vectors, and cell lines. It incorporates a variety of protein and nucleotide sequence information, assay and analytics readouts (e.g. Biacore, ELISA, FACS, etc.), generated along the process. Its modular architecture meets user-specific requirements, which allows the solution to be used through the R&D workflow. Current modules are available for Screening, Protein Engineering and Optimization, and Protein Production.

“Genedata Biologics enables customers to capitalize on the biologics market opportunity as it advances the development of innovative protein-based medicines,” said Pfannes. “It makes difficult, labor-intensive processes more efficient and can easily save pharma and biotech companies millions of R&D dollars.” •

*Molecular Medicine Tri-Conference 2011, San Francisco, Moscone Convention Center, Feb. 23-25

This article also appeared in the March-April 2011 issue of Bio-IT World Magazine. Subscriptions are free for qualifying individuals. Apply today.
Click here to login and leave a comment.  


Add Comment

Text Only 2000 character limit

Page 1 of 1

For reprints and/or copyright permission, please contact Angela Parsons, 781.972.5467.